Prosecution Insights
Last updated: April 19, 2026

Examiner: BORGEEST, CHRISTINA M

Tech Center 1600 • Art Units: 1649 1675

This examiner grants 55% of resolved cases

Performance Statistics

55.3%
Allow Rate
-4.7% vs TC avg
746
Total Applications
+21.9%
Interview Lift
1208
Avg Prosecution Days
Based on 709 resolved cases, 2023–2026

Rejection Statute Breakdown

10.0%
§101 Eligibility
18.6%
§102 Novelty
24.3%
§103 Obviousness
29.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18008324 ACVR1 (ALK2) RECEPTOR INHIBITION TO TREAT NEUROLOGICAL DISEASES Non-Final OA The Regents of the University of California
17784634 FUSION POLYPEPTIDE COMPRISING GDF15 AND POLYPEPTIDE REGION CAPABLE OF O-GLYCOSYLATION Final Rejection LG CHEM, LTD.
17490409 FSH LOWERING AGENT OR ACTIVIN PATHWAY MODIFYING AGENT TO TREAT INFERTILITY IN FEMALES Non-Final OA University Of Cincinnati
17766112 METHODS OF DETECTING circRNA Non-Final OA Washington University
17554713 Anti-CGRP Antibody Formulation Non-Final OA Eli Lilly and Company
18283665 ANTIBODY OR FRAGMENT THEREOF, AND METHOD FOR USING SAME Non-Final OA NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
17628132 ADHESIVE PROTEIN Final Rejection National University Corporation Tokai National Higher Education and Research System
17937897 METHODS FOR USING EXTRACELLULAR MICROVESICLES WITH SYNCYTIOTROPHOBLAST MARKERS TO DIAGNOSE PREECLAMPSIA Final Rejection The Trustees Of The University of Pennsylvania
17413772 BIOMARKER COMBINATIONS IN EX VIVO LUNG PERFUSION (EVLP) PERFUSATE Non-Final OA UNIVERSITY HEALTH NETWORK
17790068 BIOMARKER COMPOSITION FOR DIAGNOSING PRE-ECLAMPSIA AND USE THEREOF Non-Final OA UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
17996366 SCD83 FOR WOUND HEALING, HAIR GROWTH, AND SKIN AND HAIR CARE Final Rejection FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG
18269380 IMMUNE CHECKPOINTS Non-Final OA Vrije Universiteit Brussel
18431041 Method for Diagnosing and Assessing Endometriosis Final Rejection McMaster University
18520650 ANTI-TRKB ANTIBODIES Non-Final OA Boehringer Ingelheim International GmbH
18052426 IMMUNOSUPPRESSIVE COMPOSITION FOR USE IN TREATING IMMUNOLOGICAL DISORDERS Non-Final OA Singapore Health Services Pte Ltd
17627953 MUCIN ISOFORMS IN DISEASES CHARACTERIZED BY BARRIER DYSFUNCTION Non-Final OA Universiteit Antwerpen
17995915 METHODS FOR TREATING ANEMIA USING AN ACTRIIB LIGAND TRAP AND FEDRATINIB Final Rejection Celgene Corporation
18296763 ADM2 GENE MARKER FOR DIAGNOSIS OR PROGNOSIS PREDICTION OF THYROID CANCER AND USES THEREOF Non-Final OA The Industry & Academic Cooperation in Chungnam National University (IAC)
18334680 Glycan-Interacting Compounds and Methods of Use Non-Final OA Seagen Inc.
17909036 METHOD FOR QUANTIFYING ADIPONECTIN AND ANALYTICAL REAGENT USED THEREOF Final Rejection Tatsuya SAWAMURA
17624121 RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME Non-Final OA Palleon Pharmaceuticals Inc.
18346961 ANTI-CGRP COMPOSITIONS AND USE THEREOF Final Rejection ALDERBIO HOLDINGS LLC
18044511 A METHOD OF EVALUATING SPERM HEALTH AND IDENTIFYING SPERM TO BE USED IN ASSIS REPRODUCTIVE TECHNOLOGIES Non-Final OA The Provost, Fellows, Foundation Scholars, & The Other Members of Board, Of The College Of The Holy
18256599 ANTIBODY SPECIFICALLY BINDING TO STREP-TAG II TAG AND USE THEREOF Non-Final OA BEIJING YIMIAOYILIAO CO., LTD
17926668 Screening method for effective target - E3 ligase combinations Non-Final OA UMC Utrecht Holding B.V.
17945324 METHODS OF USING ACTIVIN RECEPTOR TYPE IIA VARIANTS Final Rejection Keros Therapeutics, Inc.
18002975 AMH AND/OR INHIBIN B AS A BIOMARKER FOR AN EFFECT OF A TREATMENT TO IMPROVE MALE FERTILITY Non-Final OA XY Therapeutics ApS
18009576 Method for Determining Risk of Pre-Term Birth Non-Final OA Arcedi Biotech ApS
17791960 NEURAL REGENERATION WITH SYNTHETIC NORRIN TRUNCATE ADMINISTRATION Final Rejection Retinal Solutions, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month